"BID" Related Products

Expand
Expand
Expand

Recombinant Human BH3 Interacting Domain Death Agonist,GST-tagged

Cat. No.: BID-1437H
Product Overview: Recombinant full-length human BID was expressed by baculovirus inSf9 insect cellsusing an N-terminal GST tag. MW = 52kDa.
Description: BID is a BH3 interacting death domain that heterodimerizes with either agonist BAX or antagonist BCL2. BID is a member of the BCL-2 family of cell death regulators and is a mediator of mitochondrial damage induced by caspase-8 (CASP8). BID initiates apoptosis by binding to regulatory sites on prosurvival BCL2 proteins to directly neutralize their function. Multiple alternatively spliced transcript variants of BID have been found, but the full-length nature of some variants has not been defined. BID together with Cathepsins play an important role in the actions of Camptothecin on breast cancer cells.
Source: Sf9 insect cells using baculovirus.
Sequence: Full-length.
Applications: Western Blot.
Storage And Stability: Store product at -70℃. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
Gene Name: BID BH3 interacting domain death agonist [ Homo sapiens ]
Synonyms: BID; BH3 interacting domain death agonist; FP497; MGC15319; MGC42355; p22 BID
Gene ID: 637
mRNA Refseq: NM_00119
Protein Refseq: NP_001187
MIM: 601997
UniProt ID: P55957
Chromosome Location: 22q11.2
Pathway: Alzheimer"s disease; Amyotrophic lateral sclerosis (ALS); Apoptosis; Natural killer cell mediated cytotoxicity; Pathways in cancer; p53 signaling pathway; Apoptosis
Function: death receptor binding; protein binding

Online Inquiry

Note: There will be extra charge for optional service!

Please input "biomart" as verification code. Please review Creative BioMart's privacy policy for more information

Optional requirements on this protein    +Expand

Price Inquiry

Welcome! For price inquiries, please feel free to contact us through the form below. We will get back to you as soon as possible.